Overcoming Drug Resistance Driven by BCL10 Mutations in Diffuse Large B Cell Lymphoma
克服弥漫性大 B 细胞淋巴瘤中 BCL10 突变导致的耐药性
基本信息
- 批准号:10512746
- 负责人:
- 金额:$ 5.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:Agammaglobulinaemia tyrosine kinaseAmericanAutomobile DrivingB lymphoid malignancyB-Cell ActivationB-LymphocytesBCL10 geneBCL6 geneBiochemicalBiologicalBiological MarkersCell LineCellsChronic Lymphocytic LeukemiaClassificationClinicalClinical TrialsComplexCyclophosphamideDataDependenceDiagnosisDiseaseDoxorubicinDrug TargetingDrug resistanceExhibitsGeneticGenetic RecombinationGoalsHematologic NeoplasmsImmuno-ChemotherapyIn VitroIncidenceIntrinsic factorLaboratoriesLeadLymphomaLymphoma cellLymphomagenesisMAPK8 geneMature B-LymphocyteMediatingMissionModelingMolecularMucosa- associated lymphoid tissue lymphoma translocation protein-1MusMutateMutationNF-kappa BNatureNon-Hodgkin&aposs LymphomaOncogenicOrganOutcomePathogenesisPathway interactionsPatient-Focused OutcomesPatientsPeptide HydrolasesPharmaceutical PreparationsPhysiciansPrednisonePrognosisPublic HealthRecurrenceRefractoryRelapseResearchResistanceRoleScientistSignal PathwaySignal TransductionSurvival AnalysisSystemTestingTherapeuticTherapeutic StudiesTyrosine Kinase InhibitorVincristinealternative treatmentbasecareerclinical decision-makingclinical heterogeneitydisorder subtypeexperimental studygenetic regulatory proteinhuman diseaseimprovedimproved outcomein vivoin vivo Modelinnovationlarge cell Diffuse non-Hodgkin&aposs lymphomamouse modelnovelnovel therapeutic interventionnovel therapeuticsoverexpressionpre-clinicalresistance mechanismresponseresponse biomarkerrituximabskillssmall moleculesynergismtargeted treatmenttherapeutic targettreatment responsetreatment strategytumor
项目摘要
Project Summary
Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma and the most common
hematologic malignancy. DLBCL exhibits significant molecular and clinical heterogeneity, yet all patients are
treated with standard chemoimmunotherapy. As such, there is a strong clinical need to identify biomarkers of
drug response and novel therapies to improve patient outcomes. BCL10 mutations are prevalent among DLBCL
subtypes and recurrent mutations frequently truncate the BCL10 protein’s regulatory C-terminus. BCL10 is a
core component of the CARD11 (CARMA1)-BCL10-MALT1 complex, which activates downstream oncogenic
pathways like JNK and NF-kB in DLBCL; however, the mechanisms by which BCL10 mutations promote
lymphomagenesis in DLBCL are poorly understood. Recent results implicate BCL10 mutations in the induction
of NF-kB signaling and MALT1 protease activity and Bruton’s Tyrosine Kinase inhibitor (BTKi) resistance. The
overall objective is to understand the role of BCL10 mutations in DLBCL, to determine mechanisms of drug
resistance and to identify alternative treatment strategies for patients with these mutations. The central
hypothesis that BCL10 mutations are activating in nature, driving lymphomagenesis and resistance to BTKis,
will be tested through the following specific aims: 1) Understand the role of BCL10 mutations in
lymphomagenesis using genetically accurate in vivo models, and 2) Identify alternative therapeutic
targets to overcome drug resistance mediated by BCL10 mutations. Aim 1 will characterize survival and
tumor incidence of a novel murine model generated in the lab containing an inducible BCL10 truncation mutation
expressed on the ROSA26 locus of C57BL/6J mice. The model mimics human disease through B-cell-specific
activation of BCL10 mutations using Cre-recombination and will also be crossed with mice overexpressing BCL6,
which occurs in context with BCL10 mutations. Aim 2 will identify compounds to attack BCL10 mutated cells
alone or in combination with BTKis by implementing small molecule synergy screens that target the BCR, NF-
kB and parallel signaling pathways. The expected outcome is the creation of genetically accurate in vivo models
of BCL10 mutations to understand their lymphomagenic potential, to define BCL10 as a biomarker of BTKi
resistance, and to identify novel, targetable dependencies induced by BCL10 mutations. The proposed research
is significant because it will uncover mechanisms of lymphomagenesis, identify biomarkers to guide clinical
decision-making in DLBCL and discover potential drug targets to overcome resistance or synergize with existing
therapies. Also, these studies are innovative because the described mouse model will be the first to characterize
BCL10 mutations in vivo and will provide a novel context to study lymphomagenesis and drug resistance driven
by BCL10 mutations. Overall, this research will have positive impacts as identifying BCL10 as a biomarker for
response to therapy and determining a therapeutic strategy for patients with BCL10 mutations will guide
treatment options and improve outcomes in DLBCL patients.
项目摘要
弥漫性大B细胞淋巴瘤(DLBCL)是一种侵袭性非霍奇金淋巴瘤,
恶性血液病DLBCL表现出显著的分子和临床异质性,但所有患者均为
用标准的化学免疫疗法治疗因此,临床上强烈需要鉴定以下生物标志物:
药物反应和新疗法,以改善患者的结果。BCL 10突变在DLBCL中普遍存在
亚型和复发突变经常截短BCL 10蛋白的调节C末端。BCL 10是一种
CARD 11(CARMA 1)-BCL 10-MALT 1复合物的核心组分,其激活下游致癌基因
DLBCL中的JNK和NF-kB等通路;然而,BCL 10突变促进DLBCL的机制
DLBCL中的淋巴瘤发生知之甚少。最近的结果暗示BCL 10突变在诱导
NF-kB信号传导和MALT 1蛋白酶活性以及布鲁顿酪氨酸激酶抑制剂(BTKi)抗性。的
总体目标是了解BCL 10突变在DLBCL中的作用,以确定药物治疗的机制,
耐药性,并确定这些突变患者的替代治疗策略。中央
假设BCL 10突变在本质上是激活的,驱动淋巴瘤发生和对BTKis的抗性,
将通过以下具体目标进行测试:1)了解BCL 10突变在
使用遗传准确的体内模型的淋巴瘤发生,和2)确定替代治疗
靶向克服由BCL 10突变介导的耐药性。目标1将描述生存率,
在实验室中产生的含有诱导型BCL 10截短突变的新型小鼠模型的肿瘤发生率
在C57 BL/6 J小鼠的ROSA 26基因座上表达。该模型通过B细胞特异性的
使用Cre重组激活BCL 10突变,并且还将与过表达BCL 6的小鼠杂交,
这发生在BCL 10突变的背景下。目标2将确定攻击BCL 10突变细胞的化合物
通过实施靶向BCR、NF-κ B和BTK的小分子协同筛选,
kB和平行信号通路。预期的结果是建立遗传准确的体内模型
BCL 10突变,以了解其淋巴瘤发生的潜力,将BCL 10定义为BTKi的生物标志物
耐药性,并确定新的,有针对性的依赖性诱导BCL 10突变。拟议研究
它将揭示淋巴瘤发生的机制,识别生物标志物以指导临床
DLBCL的决策,并发现潜在的药物靶点,以克服耐药性或与现有的
治疗此外,这些研究是创新的,因为所描述的小鼠模型将是第一个表征
BCL 10基因在体内的突变,将为研究淋巴瘤的发生和耐药性驱动提供一个新的背景
BCL 10突变总的来说,这项研究将产生积极的影响,因为确定BCL 10作为生物标志物,
对治疗的反应和确定BCL 10突变患者的治疗策略将指导
治疗选择和改善DLBCL患者的结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Caroline Alice Coughlin其他文献
Caroline Alice Coughlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Caroline Alice Coughlin', 18)}}的其他基金
Overcoming Drug Resistance Driven by BCL10 Mutations in Diffuse Large B Cell Lymphoma
克服弥漫性大 B 细胞淋巴瘤中 BCL10 突变导致的耐药性
- 批准号:
10653228 - 财政年份:2021
- 资助金额:
$ 5.18万 - 项目类别:
Overcoming Drug Resistance Driven by BCL10 Mutations in Diffuse Large B Cell Lymphoma
克服弥漫性大 B 细胞淋巴瘤中 BCL10 突变导致的耐药性
- 批准号:
10314594 - 财政年份:2021
- 资助金额:
$ 5.18万 - 项目类别:
相似海外基金
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348998 - 财政年份:2025
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
- 批准号:
2348999 - 财政年份:2025
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
Understanding Latin American Challenges in the 21st Century (LAC-EU)
了解拉丁美洲在 21 世纪面临的挑战 (LAC-EU)
- 批准号:
EP/Y034694/1 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Research Grant
Conference: North American High Order Methods Con (NAHOMCon)
会议:北美高阶方法大会 (NAHOMCon)
- 批准号:
2333724 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346565 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
REU Site: Research Experiences for American Leadership of Industry with Zero Emissions by 2050 (REALIZE-2050)
REU 网站:2050 年美国零排放工业领先地位的研究经验 (REALIZE-2050)
- 批准号:
2349580 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346564 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
Conference: Latin American School of Algebraic Geometry
会议:拉丁美洲代数几何学院
- 批准号:
2401164 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
Collaborative Research: Ionospheric Density Response to American Solar Eclipses Using Coordinated Radio Observations with Modeling Support
合作研究:利用协调射电观测和建模支持对美国日食的电离层密度响应
- 批准号:
2412294 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant
Conference: Doctoral Consortium at Student Research Workshop at the Annual Conference of the North American Chapter of the Association for Computational Linguistics (NAACL)
会议:计算语言学协会 (NAACL) 北美分会年会学生研究研讨会上的博士联盟
- 批准号:
2415059 - 财政年份:2024
- 资助金额:
$ 5.18万 - 项目类别:
Standard Grant